Clinical Trial Update: A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias [Phase 1]

View source ↗

Summary

A Phase I pediatric trial evaluating Hyper-CVAD in combination with venetoclax for relapsed or refractory acute leukemias of the lymphoid lineage, including bip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Mixed Phenotype Acute Leukemia
• Undifferentiated Leukemia

Drugs mentioned

• Hyper-CVAD regimen (Hyper-CVAD)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Refractory Acute Leukemia, Relapsed Acute Leukemia | Phase 1 | Status: RECRUITING